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NKX2-5The cardiac transcription factor GATA4 is essential for cardiac development, and mutations in this gene
have been implicated in a wide variety of congenital heart diseases in both animal models and humans.
However, whether mutated GATA4 predisposes to dilated cardiomyopathy (DCM) remains unknown. In
this study, the whole coding region and splice junction sites of the GATA4 gene was sequenced in 110
unrelated patients with idiopathic DCM. The available relatives of the index patient harboring an identi-
ﬁed mutation and 200 unrelated ethnically matched healthy individuals used as controls were geno-
typed. The functional effect of the mutant GATA4 was characterized in contrast to its wild-type
counterpart using a luciferase reporter assay system. As a result, a novel heterozygous GATA4 mutation,
p.C271S, was identiﬁed in a family with DCM inherited as an autosomal dominant trait, which co-segre-
gated with DCM in the family with complete penetrance. The missense mutation was absent in 400 con-
trol chromosomes and the altered amino acid was completely conserved evolutionarily among species.
Functional analysis demonstrated that the GATA4 mutant was associated with signiﬁcantly decreased
transcriptional activity and remarkably reduced synergistic activation between GATA4 and NKX2-5,
another transcription factor crucial for cardiogenesis. The ﬁndings provide novel insight into the molec-
ular mechanisms involved in the pathogenesis of DCM, suggesting the potential implications in the
prenatal diagnosis and gene-speciﬁc treatment for this common form of myocardial disorder.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
Dilated cardiomyopathy (DCM), the most common form of pri-
mary myocardial disorder characterized by ventricular chamber
enlargement and contractile dysfunction with normal left ventric-
ular wall thickness, is a major cause of congestive heart failure and
sudden cardiac death and is the leading indication for cardiac
transplantation in patients worldwide [1]. Approximately 50% of
DCM cases are idiopathic, of which 25%–50% are familial, withestimates that vary based on the family members screened [2]. A
growing body of evidence demonstrates that genetic risk factors
play an important role in the pathogenesis of idiopathic DCM,
and a long list of mutations in at least 50 single genes have been
linked to familial HCM [2]. Functional characterization of these ge-
netic variations indicates that multiple defects in myocardial struc-
tures and cardiac signal molecules may lead to DCM [2]. Despite
the seemingly vast number of genes and mutations associated with
DCM, the molecular basis for HCM in an overwhelming majority of
patients remains unclear.
The zinc-ﬁnger transcription factor GATA4 is highly expressed
in cardiomyocytes at different developmental stages and continues
expression in the adult cardiac myocytes, where it regulates the
transcription of several key structural and regulatory genes,
including atrial natriuretic factor (ANF), brain natriuretic factor,
carnitine palmitoyltransferase Ib, troponin I, troponin C, a- and
b-myosin heavy chain [3–5]. In humans, GATA4 has been demon-
strated to be crucial for normal cardiogenesis, as shown by the
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congenital cardiovascular abnormalities, including atrial septal de-
fect (ASD), ventricular septal defect, tetralogy of Fallot, endocardial
cushion defect, patent ductus arteriosus, pulmonary stenosis, and
hypoplastic right ventricle [6–9]. In mice, homozygous GATA4 deﬁ-
ciency results in early embryonic lethality because of abnormal
embryogenesis and heart tube formation [10,11]. In contrast, mice
expressing 70% less GATA4 protein died between days 13.5 and
16.5 of gestation, and in these embryos, common atrioventricular
canal, double outlet right ventricle and hypoplastic ventricular
myocardium were observed [12]. Furthermore, transgenic mice
expressing GATA4 mutants showed various cardiac malformations,
including septal defects, right ventricular hypoplasia, endocardial
cushion defect, tetralogy of Fallot, double outlets of the right ven
tricle, and cardiomyopathy, similar to the anomalies seen in
humans [8]. More importantly, gene-targeted mice with marked
loss of GATA4 protein in the heart survived into adulthood but
displayed progressive cardiac enlargement and dysfunction with
increased rates of cardiomyocyte apoptosis that was correlated to
GATA4 levels [13]. These data highlight the pivotal role of GATA4
in maintaining proper homeostatic remodeling in adult hearts by
promoting cell survival and regeneration and inhibiting pro-
grammed cell death [14–17].
GATA4 regulates cardiac gene expression by forming complexes
with other transcriptional factors, including NKX2-5, TBX5, SRF,
SMAD1, SMAD4, and JARID2 [5]. NKX2-5 is another critical regula-
tor of cardiac development with expression and functions that
overlap with GATA4 during embryogenesis [9]. Moreover, GATA4
and NKX2-5 physically interact and have been shown to coopera-
tively regulate the expression of multiple essential cardiac target
genes, including those encoding ANF, T- and L-type Ca2+ channels,
connexin40, a-actin, ID2 and LRRC10 [5]. Targeted knockout of
NKX2-5 in mice gives rise to impaired cardiac growth and chamber
formation, deranged gene regulatory network, and early embry-
onic death, while cardiac-speciﬁc deletion of NKX2-5 causes
progressive cardiomyopathy and complete heart block [1–20].
Mutations in the human NKX2-5 gene have been related to a di-
verse range of congenital heart diseases, including atrial and ven-
tricular septal defects, tetralogy of Fallot, hypoplastic left heart,
transposition of the great arteries, valvular malformations, left
ventricular contractile dysfunction, and DCM [21–23]. These re-
sults justify screening GATA4 as a prime candidate gene for DCM.
2. Materials and methods
2.1. Study population
A total of 110 unrelated patients with idiopathic DCM were
recruited from the Han Chinese population. The available relatives
of the index patients were also enrolled. The controls were 200
ethnically-matched unrelated healthy individuals. All participants
were evaluated by detailed history, physical examination, chest
radiography, electrocardiogram, echocardiography, and exercise
performance testing. Cardiac catheterization, angiography, endo-
myocardial biopsy, and cardiac magnetic resonance imaging were
performed only if there was a strong clinical indication. Medical re-
cords were also reviewed in the case of deceased or unavailable
relatives. Diagnosis of idiopathic DCM was made in accordance
with the criteria established by the World Health Organization/
International Society and Federation of Cardiology Task Force on
the Classiﬁcation of Cardiomyopathy: a left ventricular end-dia-
stolic diameter >27 mm/m2 and an ejection fraction <40% or frac-
tional shortening <25% in the absence of abnormal loading
conditions, coronary artery disease, congenital heart lesions, and
other systemic diseases [24]. Individuals were excluded if they
had insufﬁcient echocardiographic image quality, or coexistentconditions that may lead to contractile dysfunction, such as uncon-
trolled systemic hypertension, coronary artery disease, or valvular
heart disease. Familial DCM was deﬁned as having two or more
ﬁrst-degree relatives with idiopathic DCM. Peripheral venous
blood specimens from the study subjects and control individuals
were prepared. All clinical studies were performed with investiga-
tors blinded to the results of genetic testing. This study conformed
to the principles of the Declaration of Helsinki and the study pro-
tocol was approved by the local institutional ethics committee.
Written informed consent was obtained from all participants prior
to investigation.
2.2. Genetic studies
Genomic DNA was extracted from blood lymphocytes of all par-
ticipants with Wizard Genomic DNA Puriﬁcation Kit (Promega,
Madison, WI, USA). The whole coding region and splice junction
sites of the GATA4 gene was sequenced in 110 unrelated patients
with idiopathic DCM. Genotyping GATA4 in the available relatives
of the proband carrying an identiﬁed mutation and 200 unrelated
healthy controls was performed. The referential genomic DNA
sequence of GATA4 derived from GenBank (accession No.
NC_000008). The primer pairs used to amplify the coding exons
and intron–exon boundaries of GATA4 by polymerase chain reac-
tion (PCR) were designed as described previously [25]. The PCR
was carried out using HotStar Taq DNA Polymerase (Qiagen, Hil-
den, Germany) on a PE 9700 Thermal Cycler (Applied Biosystems,
Foster, CA, USA) with standard conditions and concentrations of re-
agents. Ampliﬁed products were puriﬁed with the QIAquick Gel
Extraction Kit (Qiagen). Both strands of each PCR product were se-
quenced with a BigDye Terminator v3.1 Cycle Sequencing Kit (Ap-
plied Biosystems) under an ABI PRISM 3130 XL DNA Analyzer
(Applied Biosystems). DNA sequences were viewed and analyzed
with the DNA Sequencing Analysis Software v5.1 (Applied Biosys-
tems). The variant was validated by resequencing of an indepen-
dent PCR-generated amplicon from the subject. In addition, for
an identiﬁed sequence variant, the single nucleotide polymor-
phism (SNP; http://www.ncbi.nlm.nih.gov/SNP) and Exome Vari-
ant Server (EVS; http://evs.gs.washington.edu/EVS) databases
were queried to conﬁrm its novelty.
2.3. Multiple sequence alignments
Multiple GATA4 protein sequences across various species were
aligned using the online MUSCLE program, version 3.6 (http://
www.ncbi.nlm.nih.gov/).
2.4. Plasmids and site-directed mutagenesis
The recombinant expression plasmids GATA4-pSSRa, NKX2-5-
pEFSA, and ANF-luciferase reporter (ANF-luc), which contains the
2600-bp 50-ﬂanking region of the ANF gene, were kindly provided
by Dr. Ichiro Shiojima from Chiba University School of Medicine,
Japan. The identiﬁed mutation was introduced into the wild-type
GATA4 using a QuickChange II XL Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA, USA) with a complementary pair of prim-
ers. The mutant was sequenced to conﬁrm the desired mutation
and to exclude any other sequence variations.
2.5. Reporter gene assays
Hela cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal calf serum. The internal control re-
porter plasmid pGL4.75 (hRluc/CMV, Promega) were used in tran-
sient transfection assays to examine the transcriptional activity of
the GATA4 mutant. Hela cells were transfected with 0.4 lg of wild-
R.-G. Li et al. / Biochemical and Biophysical Research Communications 439 (2013) 591–596 593type or mutant GATA4-pSSRa, 1.0 lg of ANF-luc, and 0.04 lg
of pGL4.75 using PolyFect Transfection Reagent (Qiagen). For
co-transfection experiments, 0.2 lg of wild-type GATA4-pSSRa,
0.2 lg of mutant GATA4-pSSRa, 1.0 lg of ANF-luc, and 0.04 lg of
pGL4.75 were used. Fireﬂy luciferase and Renilla luciferase activi-
ties were measured with the Dual-Glo luciferase assay system
(Promega) 48 h after transfection. The activity of the ANF promoter
was presented as fold activation of Fireﬂy luciferase relative to
Renilla luciferase. Three independent experiments were performed
at minimum for wild-type and mutant GATA4.
For the analysis of the synergistic transcriptional activation be-
tween GATA4 and NKX2-5 [26], COS-7 cells were grown and trans-
fected with 0.2 lg of wild-type or mutant GATA4-pSSRa, alone or
together with 0.2 lg of wild-type NKX2-5-pEFSA, 1.0 lg of ANF-
luc, and 0.04 lg of pGL4.75 using PolyFect Transfection Reagent
(Qiagen). When both wild-type and mutant GATA4-pSSRa were
co-transfected, 0.1 lg of each GATA4-pSSRa was used.
2.6. Statistical analysis
Data are expressed as means ± SD. Continuous variables were
tested for normality of distribution and student’s unpaired t test
was used for comparison of numeric variables between two
groups. Comparison of the categorical variables between two
groups was performed using Pearson’s v2 test or Fisher’s exact test
when appropriate. A 2-tailed p value of <0.05 indicated statistical
signiﬁcance.3. Results
3.1. Characteristics of the study subjects
A total of 110 unrelated patients with idiopathic DCM were
clinically evaluated in contrast to 200 control individuals. None
of them had overt traditional risk factors for DCM. All the patients
manifested with typical DCM phenotype as described previously
[24]. The control individuals had no evidence of organic cardiac
diseases, and their echocardiogram results were normal. The base-
line clinical characteristics of the study subjects are summarized in
Table 1.
3.2. Novel GATA4 mutation
By direct sequencing of the GATA4 gene, a heterozygous
mutation was identiﬁed in 1 out of 110 unrelated patients withTable 1
The baseline clinical characteristics of the study subjects.
Patients (n = 110) Controls (n = 200)
Age (years) 51.8 ± 13.7 52.1 ± 11.4
Male (%) 68 (61.8) 120 (60.0)
Family history of DCM (%) 42 (38.2) 0 (0)
SBP (mmHg) 113.5 ± 16.1 118.3 ± 12.9
DBP (mmHg) 72.2 ± 9.4 80.5 ± 6.3
HR (bpm) 108.6 ± 15.2 76.7 ± 10.8
LVEDD (mm) 70.1 ± 8.4 48.6 ± 6.7
LVESD (mm) 57.5 ± 9.1 35.3 ± 6.5
LVEF (%) 35.2 ± 10.6 64.3 ± 7.0
NYHA function class (%)
I 18 (16.4) NA
II 42 (38.2) NA
III 38 (34.5) NA
IV 12 (10.9) NA
DCM indicates dilated cardiomyopathy; SBP, systolic blood pressure; DBP, diastolic
blood pressure; HR, heart rate; LVEDD, left ventricular end-diastolic diameter;
LVESD, left ventricular end-systolic diameter; LVEF, left ventricular ejection frac-
tion; NYHA, New York Heart Association; and NA, not applicable.idiopathic DCM, with a mutational prevalence of approximately
0.91%. Speciﬁcally, a substitution of C for G in the second nucleo-
tide of codon 271 (c.812G >C), predicting the transition of cysteine
(C) into serine (S) at amino acid position 271 (p.C271S) was de-
tected in the proband from family 1. The sequence chromatograms
showing the observed heterozygous GATA4 mutation of c.812G >C
compared with its control sequence are shown in Fig. 1A. A sche-
matic diagram of GATA4 depicting the structural domains and
location of the mutation identiﬁed in this study is presented in
Fig. 1B. The missense mutation was neither found in the control
population nor reported in the SNP and EVS databases. The genetic
scan of the family showed that the mutation was present in all af-
fected living family members, but absent in unaffected family
members examined. Analysis of the pedigree demonstrated that
the mutation co-segregated with DCM transmitted as an autoso-
mal dominant trait in the family with complete penetrance. The
pedigree structure of the family is illustrated in Fig. 1C. The pheno-
typic characteristics of the affected living family members are
listed in Table 2.
Additionally, the proband’s son had also ﬁrst-degree atrioven-
tricular conduction block. Individual III-7 had congenital ASD as
well as paroxysmal atrial ﬁbrillation (AF), and his son also had
congenital ASD.
3.3. Alignment of multiple GATA4 protein sequences across species
A cross-species alignment of GATA4 protein sequences showed
that the altered amino acid was completely conserved evolution-
arily (Fig. 2).
3.4. Transcriptional activity of the GATA4 mutant
As shown in Fig. 3, the same amount (0.4 lg) of wild-type and
mutant GATA4 activated the ANF promoter by 10-fold and 2-
fold, respectively. When the same amount of wild-type GATA4
(0.2 lg) was cotransfected with mutant GATA4 (0.2 lg), the in-
duced activation of the ANF promoter was 5-fold. These results
suggest that the GATA4 mutant has a signiﬁcantly reduced activa-
tion activity compared with wild-type counterpart.
3.5. Synergistic transcriptional activity between GATA4 mutant
and NKX2-5
As shown in Fig. 4, in the presence of 0.2 lg of wild-type NKX2-
5, the same amount (0.2 lg) of wild-type and mutant GATA4 acti-
vated the ANF promoter by 22-fold and 8-fold, respectively.
When the same amount of wild-type GATA4 (0.1 lg) was cotrans-
fected with mutant GATA4 (0.1 lg), the induced activation of the
ANF promoter was 15-fold, indicating that the GATA4 mutant
has a signiﬁcantly decreased synergistic transactivational activity
with NKX2-5.4. Discussion
In the current study, a novel heterozygous GTA4 mutation of
p.C271S was identiﬁed in a family with DCM. The missense muta-
tion co-segregated with DCM in the family and was absent in the
400 reference chromosomes from an ethnically matched control
population. A cross-species alignment of multiple GATA4 protein
sequences displayed that the altered amino acid was completely
conserved evolutionarily. Functional analysis revealed that the
mutant were associated with signiﬁcantly decreased transcrip-
tional activity alone or in synergy with NKX2-5. Therefore, it is
very likely that genetically compromised GATA4 contributes to
the DCM in these mutation carriers.
Fig. 1. GATA4 C271S mutation associated with dilated cardiomyopathy. (A), sequence electropherogram showing the GATA4 variation compared with its control. The arrow
indicates the heterozygous nucleotides of C/G in the proband (mutant) or the homozygous nucleotides of G/G in the corresponding control individual (wild-type). The
rectangle denotes the nucleotides comprising a codon of GATA4. (B), schematic diagram of GATA4 protein structure with the dilated cardiomyopathy related mutation
indicated. The mutation found in patients with dilated cardiomyopathy is shown above the structural domains. NH2 means amino-terminus; TAD, transcriptional activation
domain; ZF, zinc ﬁnger; NLS, nuclear localization signal; COOH, carboxyl-terminus. (C), pedigree structure of the family with dilated cardiomyopathy. Family members are
identiﬁed by generations and numbers. Square indicates male family member; circle, female member; symbol with a slash, the deceased member; closed symbol, affected
member; open symbol, unaffected member; arrow, proband; ‘‘+’’, carrier of the heterozygous missense mutation; and ‘‘’’, non-carrier.
Table 2
Phenotypic characteristics of the affected living pedigree members.
Individual Gender Age (years) Cardiac phenotype LVEDD (mm) LVESD (mm) LVEF (%) ECG ﬁndings
III-4 F 52 DCM 74.6 62.4 36.3
III-7 M 48 DCM, ASD 65.7 53.9 41.0 AF
IV-2 M 26 DCM 58.8 48.0 47.5 AVB
IV-4 F 23 DCM, ASD 60.2 49.5 38.6
M denotes male; F, female; DCM, dilated cardiomyopathy; ASD, atrial septal defect; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic
diameter; LVEF, left ventricular ejection fraction; AF, atrial ﬁbrillation; AVB, atrioventricular conduction block; NA, not available or not applicable.
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scriptional activator of multiple genes expressed during cardiac
development including ANF gene [5]. GATA4 may bind to target
DNA in conjunction with other partners including transcription
factor NKX2-5, and the synergistic transcriptional activation
mediated by NKX2-5 has been veriﬁed [6,26]. Hence, the functional
characteristics of the GATA4 mutation may be explored by analysis
of the transcriptional activity of the ANF promoter in cells express-ing GATA4 with or without NKX2-5. In the present study, the func-
tional effect of the novel p.C271S mutation of GATA4 identiﬁed in
our familial DCM patients was investigated by transcriptional
activity assays and the results showed decreased transcriptional
activity and diminished synergistic activation with NKX2-5 on a
target gene. These ﬁndings imply that haploinsufﬁciency or
dominant-negative effect resulting from GATA4 mutation is poten-
tially an alternative pathological mechanism underling DCM.
Fig. 2. Alignment of multiple GATA4 protein sequences across species. The altered amino acid of p.C271 is completely conserved evolutionarily among species.
Fig. 3. Functional defects associated with GATA4 mutation. Activation of atrial
natriuretic factor promoter driven luciferase reporter in Hela cells by wild-type
(WT) or mutant GATA4, alone or in combination, showed signiﬁcantly decreased
transactivational activity by the mutant protein. Experiments were performed in
triplicate, and mean and standard deviations are shown. ⁄⁄ and ⁄ represent
p < 0.001 and p < 0.005, respectively, when compared with wild-type GATA4.
Fig. 4. Reduced synergistic transcriptional activation with NKX2-5 caused by
GATA4 mutation. The synergistic activation of the atrial natriuretic factor promoter
in COS-7 cells by NKX2-5 and mutant GATA4 was signiﬁcantly reduced compared
with that by NKX2-5 and wild-type GATA4. Experiments were performed in
triplicate, and mean and standard deviations are shown. ⁄⁄ represents p < 0.001 and
⁄ represents p < 0.01, when compared with NKX2-5 and wild-type GATA4.
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ceptibility to DCM may be partially attributed to the developmen-
tal and regenerative defects of the myocardium as well as
abnormal heart remodeling. During embryogenesis, GATA4 is crit-
ical for activation and maintenance of the core cardiac regulatory
network, and GATA4-null mutations compromise cardiomyocyte
speciﬁcation and maturation, leading to death [27]. GATA4 is also
pivotal for postnatal maturation and homeostasis of cardiomyo-
cytes, and adult heart function and adaptation [13]. The mice with
cardiomyocyte-speciﬁc deletion of GATA4 were viable and
survived into adulthood, but they presented with a progressive
deterioration in cardiac function and dilation in adulthood. More-
over, in this mouse model pressure overload or exercise stimula-
tion failed to induce cardiac hypertrophy, but induced rapid
decompensation, precipitous heart failure and increased apoptosis
[13]. In contrast, overexpression of GATA4 in the heart was sufﬁ-
cient for inducing cardiac hypertrophy [28]. In humans, mutations
in the transcriptionally cooperative partners of GATA4, including
NKX2-2 and TBX20, have been associated with familial DCM
[23,29]. Taken together, these data support that GATA4 mutation
predisposes to DCM.
Additionally, some important cardiac genes were activated by
GATA4, and mutations in multiple target molecules have been
implicated in DCM, including a-actin, amyosin heavy chain, tropo-
nin C, and troponin I [2,5]. Therefore, mutated GATA4 probably en-
hances vulnerability to DCM by reducing expression of target
genes.
Similar with previous reports [6–9,30–32], in this study,
congenital heart disease was observed in two patients bearing
the GATA4 mutation, and one mutation carrier had also AF. The
phenotypic variability within this family may be explained by
the following reasons. Firstly, AF may occur as rarely as a few times
in a lifetime for some patients and a longer duration of electrocar-
diographic monitoring is needed to record paroxysmal AF. Next, AF
occurs more commonly in older patients and some carriers may
not be old enough to develop AF. Thirdly, some congenital cardiac
structural defects may close spontaneously, hence we cannot rule
out the possibility that some mutation carriers with DCM had
minor cardiac defects that closed shortly after birth on their own.
Finally, different genetic backgrounds and environmental risk
factors may be responsible for the variable penetrance of the
phenotype.
In conclusion, the current study ﬁrstly links GATA4 loss-
of-function mutation to DCM and provides novel insight into the
molecular mechanisms implicated in the pathogenesis of DCM,
implying potential implications in early prophylaxis and gene-
speciﬁc treatment of this common cardiomyopathy.
596 R.-G. Li et al. / Biochemical and Biophysical Research Communications 439 (2013) 591–596Acknowledgments
We are thankful to the participants for their dedication to the
study. This work was supported by grants from the National Natu-
ral Science Fund of China (81070153, 81270161 and 81270231),
and the National Basic Research Program of China
(2010CB912604).
References
[1] N.K. Lakdawala, J.R. Winterﬁeld, B.H. Funke, Dilated cardiomyopathy, Circ.
Arrhythm. Electrophysiol. 6 (2013) 228–237.
[2] E.M. McNally, J.R. Golbus, M.J. Puckelwartz, Genetic mutations and
mechanisms in dilated cardiomyopathy, J. Clin. Invest. 123 (2013) 19–26.
[3] S. Pikkarainen, H. Tokola, R. Kerkelä, H. Ruskoaho, GATA transcription factors in
the developing and adult heart, Cardiovasc. Res. 63 (2004) 196–207.
[4] C. Perrino, H.A. Rockman, GATA4 and the two sides of gene expression
reprogramming, Circ. Res. 98 (2006) 715–716.
[5] M.J. Brody, E. Cho, M.R. Mysliwiec, T.G. Kim, C.D. Carlson, K.H. Lee, Y. Lee,
Lrrc10 is a novel cardiac-speciﬁc target gene of Nk2-5 and GATA4, J. Mol. Cell
Cardiol. 62 (2013) 237–246.
[6] V. Garg, I.S. Kathiriya, R. Barnes, M.K. Schluterman, I.N. King, C.A. Butler, C.R.
Rothrock, R.S. Eapen, K. Hirayama-Yamada, K. Joo, R. Matsuoka, J.C. Cohen, D.
Srivastava, GATA4 mutations cause human congenital heart defects and reveal
an interaction with TBX5, Nature 424 (2003) 443–447.
[7] G. Nemer, F. Fadlalah, J. Usta, M. Nemer, G. Dbaibo, M. Obeid, F. Bitar, A novel
mutation in the GATA4 gene in patients with Tetralogy of Fallot, Hum. Mutat.
27 (2006) 293–294.
[8] S.K. Rajagopal, Q. Ma, D. Obler, J. Shen, A. Manichaikul, A. Tomita-Mitchell, K.
Boardman, C. Briggs, V. Garg, D. Srivastava, E. Goldmuntz, K.W. Broman, D.W.
Benson, L.B. Smoot, W.T. Pu, Spectrum of heart disease associated with murine
and human GATA4 mutation, J. Mol. Cell Cardiol. 43 (2007) 677–685.
[9] D.J. McCulley, B.L. Black, Transcription factor pathways and congenital heart
disease, Curr. Top Dev. Biol. 100 (2012) 253–277.
[10] J.D. Molkentin, Q. Lin, S.A. Duncan, E.N. Olson, Requirement of the
transcription factor GATA4 for heart tube formation and ventral
morphogenesis, Genes Dev. 11 (1997) 1061–1072.
[11] C.T. Kuo, E.E. Morrisey, R. Anandappa, K. Sigrist, M.M. Lu, M.S. Parmacek, C.
Soudais, J.M. Leiden, GATA4 transcription factor is required for ventral
morphogenesis and heart tube formation, Genes Dev. 11 (1997) 1048–1060.
[12] W.T. Pu, T. Ishiwata, A.L. Juraszek, Q. Ma, S. Izumo, GATA4 is a dosage-sensitive
regulator of cardiac morphogenesis, Dev. Biol. 275 (2004) 235–244.
[13] T. Oka, M. Maillet, A.J. Watt, R.J. Schwartz, B.J. Aronow, S.A. Duncan, J.D.
Molkentin, Cardiac-speciﬁc deletion of Gata4 reveals its requirement for
hypertrophy, compensation, and myocyte viability, Circ. Res. 98 (2006) 837–
845.
[14] Y.J. Suzuki, T. Evans, Regulation of cardiac myocyte apoptosis by the GATA-4
transcription factor, Life Sci. 74 (2004) 1829–1838.
[15] K. Kikuchi, J.E. Holdway, A.A. Werdich, R.M. Anderson, Y. Fang, G.F. Egnaczyk, T.
Evans, C.A. Macrae, D.Y. Stainier, K.D. Poss, Primary contribution to zebraﬁsh
heart regeneration by gata4(+) cardiomyocytes, Nature 464 (2010) 601–605.
[16] L. Qian, Y. Huang, C.I. Spencer, A. Foley, V. Vedantham, L. Liu, S.J. Conway, J.D.
Fu, D. Srivastava, In vivo reprogramming of murine cardiac ﬁbroblasts into
induced cardiomyocytes, Nature 485 (2012) 593–598.
[17] K. Song, Y.J. Nam, X. Luo, X. Qi, W. Tan, G.N. Huang, A. Acharya, C.L. Smith, M.D.
Tallquist, E.G. Neilson, J.A. Hill, R. Bassel-Duby, E.N. Olson, Heart repair by
reprogramming non-myocytes with cardiac transcription factors, Nature 485
(2012) 599–604.[18] I. Lyons, L.M. Parsons, L. Hartley, R. Li, J.E. Andrews, L. Robb, R.P. Harvey,
Myogenic and morphogenetic defects in the heart tubes of murine embryos
lacking the homeo box gene Nk2-5, Genes Dev. 9 (1995) 1654–1666.
[19] O.W. Prall, M.K. Menon, M.J. Solloway, Y. Watanabe, S. Zaffran, F. Bajolle, C.
Biben, J.J. McBride, B.R. Robertson, H. Chaulet, F.A. Stennard, N. Wise, D. Schaft,
O. Wolstein, M.B. Furtado, H. Shiratori, K.R. Chien, H. Hamada, B.L. Black, Y.
Saga, E.J. Robertson, M.E. Buckingham, R.P. Harvey, An Nk2-5/Bmp2/Smad1
negative feedback loop controls heart progenitor speciﬁcation and
proliferation, Cell 128 (2007) 947–959.
[20] M. Pashmforoush, J.T. Lu, H. Chen, T.S. Amand, R. Kondo, S. Pradervand, S.M.
Evans, B. Clark, J.R. Feramisco, W. Giles, S.Y. Ho, D.W. Benson, M. Silberbach, W.
Shou, K.R. Chien, Nk2-5 pathways and congenital heart disease; loss of
ventricular myocyte lineage speciﬁcation leads to progressive cardiomyopathy
and complete heart block, Cell 117 (2004) 373–386.
[21] J.J. Schott, D.W. Benson, C.T. Basson, W. Pease, G.M. Silberbach, J.P. Moak,
B.J. Maron, C.E. Seidman, J.G. Seidman, Congenital heart disease caused by
mutations in the transcription factor NKX2-5, Science 281 (1998) 108–
111.
[22] S.M. Reamon-Buettner, J. Borlak, NKX2-5: an update on this hypermutable
homeodomain protein and its role in human congenital heart disease (CHD),
Hum. Mutat. 31 (2010) 1185–1194.
[23] M.W. Costa, G. Guo, O. Wolstein, M. Vale, M.L. Castro, L. Wang, R. Otway, P.
Riek, N. Cochrane, M. Furtado, C. Semsarian, R.G. Weintraub, T. Yeoh, C.
Hayward, A. Keogh, P. Macdonald, M. Feneley, R.M. Graham, J.G. Seidman, C.E.
Seidman, N. Rosenthal, D. Fatkin, R.P. Harvey, Functional characterization of a
novel mutation in NKX2-5 associated with congenital heart disease and adult-
onset cardiomyopathy, Circ. Cardiovasc. Genet. 6 (2013) 238–247.
[24] P. Elliott, C. O’Mahony, P. Syrris, A. Evans, C. Rivera Sorensen, M.N. Sheppard, G.
Carr-White, A. Pantazis, W.J. McKenna, Prevalence of desmosomal protein
gene mutations in patients with dilated cardiomyopathy, Circ. Cardiovasc.
Genet. 3 (2010) 314–322.
[25] X.Y. Liu, J. Wang, J.H. Zheng, K. Bai, Z.M. Liu, X.Z. Wang, X. Liu, W.Y. Fang, Y.Q.
Yang, Involvement of a novel GATA4 mutation in atrial septal defects, Int. J.
Mol. Med. 28 (2011) 17–23.
[26] W. Zhu, I. Shiojima, Y. Hiroi, Y. Zou, H. Akazawa, M. Mizukami, H. Toko, Y.
Yazaki, R. Nagai, I. Komuro, Functional analyses of three Csx/Nkx-2.5
mutations that cause human congenital heart disease, J. Biol. Chem. 275
(2000) 35291–35296.
[27] J. Schlesinger, M. Schueler, M. Grunert, J.J. Fischer, Q. Zhang, T. Krueger, M.
Lange, M. Tönjes, I. Dunkel, S.R. Sperling, The cardiac transcription network
modulated by Gata4, Mef2a, Nkx2.5, Srf, histone modiﬁcations, and
microRNAs, PLoS Genet. 7 (2011). e1001313.
[28] Q. Liang, L.J. De Windt, S.A. Witt, T.R. Kimball, B.E. Markham, J.D. Molkentin,
The transcription factors GATA4 and GATA6 regulate cardiomyocyte
hypertrophy in vitro and in vivo, J. Biol. Chem. 276 (2001) 30245–30253.
[29] E.P. Kirk, M. Sunde, M.W. Costa, S.A. Rankin, O. Wolstein, M.L. Castro, T.L.
Butler, C. Hyun, G. Guo, R. Otway, J.P. Mackay, L.B. Waddell, A.D. Cole, C.
Hayward, A. Keogh, P. Macdonald, L. Grifﬁths, D. Fatkin, G.F. Sholler, A.M. Zorn,
M.P. Feneley, D.S. Winlaw, R.P. Harvey, Mutations in cardiac T-box factor gene
TBX20 are associated with diverse cardiac pathologies, including defects of
septation and valvulogenesis and cardiomyopathy, Am. J. Hum. Genet. 81
(2007) 280–291.
[30] Y.Q. Yang, M.Y. Wang, X.L. Zhang, H.W. Tan, H.F. Shi, W.F. Jiang, X.H. Wang,
W.Y. Fang, X. Liu, GATA4 loss-of-function mutations in familial atrial
ﬁbrillation, Clin. Chim. Acta 412 (2011) 1825–1830.
[31] J.Q. Jiang, F.F. Shen, W.Y. Fang, X. Liu, Y.Q. Yang, Novel GATA4 mutations in
lone atrial ﬁbrillation, Int. J. Mol. Med. (2011) 1025–1032.
[32] J. Wang, Y.M. Sun, Y.Q. Yang, Mutation spectrum of the GATA4 gene in
patients with idiopathic atrial ﬁbrillation, Mol. Biol. Rep. 39 (2012) 8127–
8135.
